Genprex, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Genprex, Inc. (GNPX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 95 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-14
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was 95.00 shares.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 1.00 shares, a 97.73% decline from fiscal 2024.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 44.00 shares, a 99.30% decline from fiscal 2023.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 6.25K shares, a 274.40% increase from fiscal 2022.
- Genprex, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 1.67K shares, a 98.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 95.00 shares 10-Q · filed 2026-08-14 | 95.00 shares 10-Q · filed 2026-08-14 | 95.00 shares derived: sum of 3 quarters · filed 2026-08-14 | 95.00 shares derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-08-14 | 0.00 shares derived: sum of 2 quarters · filed 2026-08-14 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-14 | 0.00 shares derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-30 | 0.00 shares derived: sum of 3 quarters · filed 2026-08-14 | 1.00 shares 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2026-08-14 | 1.00 shares 10-Q · filed 2025-11-14 | 4.00 shares derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-14 | 0.00 shares 10-Q · filed 2026-08-14 | 63.00 shares 10-Q · filed 2025-08-14 | 4.00 shares derived: sum of 3 quarters · filed 2026-08-14 | 13.00 shares derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | 1.00 shares 10-Q · filed 2026-08-14 | 63.00 shares 10-Q · filed 2025-05-12 | 4.00 shares derived: sum of 2 quarters · filed 2026-08-14 | 13.00 shares derived: sum of 3 quarters · filed 2026-08-14 | 36.00 shares derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2024-12-31 | 3.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 12.00 shares derived: sum of 2 quarters · filed 2026-03-30 | 35.00 shares derived: sum of 3 quarters · filed 2026-03-30 | 44.00 shares 10-K · filed 2026-03-30 | 2.25K shares 10-K · filed 2025-04-01 | |||
| 2024-09-30 | 9.00 shares 10-Q · filed 2025-11-14 | 460.00 shares 10-Q · filed 2024-11-13 | 32.00 shares derived: sum of 2 quarters · filed 2025-11-14 | 41.00 shares 10-Q · filed 2025-11-14 | 2.09K shares 10-Q · filed 2024-11-13 | 5.98K shares derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | 23.00 shares 10-Q · filed 2025-11-14 | 1.19K shares 10-Q · filed 2024-08-09 | 1.63K shares 10-Q · filed 2025-08-14 | 5.97K shares derived: sum of 3 quarters · filed 2025-11-14 | 6.28K shares derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-03-31 | 9.00 shares 10-Q · filed 2025-11-14 | 438.00 shares 10-Q · filed 2024-05-15 | 5.95K shares derived: sum of 2 quarters · filed 2025-11-14 | 6.25K shares derived: sum of 3 quarters · filed 2025-11-14 | 6.25K shares derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2023-12-31 | 5.94K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | 6.25K shares derived: sum of 2 quarters · filed 2025-04-01 | 6.25K shares derived: sum of 3 quarters · filed 2025-04-01 | 6.25K shares 10-K · filed 2025-04-01 | ||||
| 2023-09-30 | 308.00 shares 10-Q · filed 2024-11-13 | 12.29K shares 10-Q · filed 2023-11-14 | 308.00 shares derived: sum of 2 quarters · filed 2024-11-13 | 308.00 shares 10-Q · filed 2024-11-13 | 12.29K shares 10-Q · filed 2023-11-14 | -64.69K shares derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-13 | -65.00K shares derived: sum of 3 quarters · filed 2024-11-13 | -15.83K shares derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-11-13 | -65.00K shares derived: sum of 2 quarters · filed 2024-11-13 | -15.83K shares derived: sum of 3 quarters · filed 2024-11-13 | -15.83K shares derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2022-12-31 | -65.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -15.83K shares derived: sum of 2 quarters · filed 2024-04-01 | -15.83K shares derived: sum of 3 quarters · filed 2024-04-01 | 1.67K shares 10-K · filed 2024-04-01 | 66.67K shares 10-K · filed 2023-03-31 | |||
| 2022-09-30 | 49.17K shares 10-Q · filed 2023-11-14 | 49.17K shares derived: sum of 2 quarters · filed 2023-11-14 | 66.67K shares 10-Q · filed 2023-11-14 | 175.17K shares derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | 17.50K shares 10-Q · filed 2023-08-21 | 126.01K shares derived: sum of 3 quarters · filed 2023-11-14 | 126.01K shares derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-03-31 | 17.50K shares 10-Q · filed 2023-11-14 | 126.01K shares derived: sum of 2 quarters · filed 2023-11-14 | 126.01K shares derived: sum of 3 quarters · filed 2023-11-14 | 126.01K shares derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2021-12-31 | 108.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 108.51K shares derived: sum of 2 quarters · filed 2023-03-31 | 108.51K shares derived: sum of 3 quarters · filed 2023-03-31 | 118.51K shares 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-15 | 10.00K shares 10-Q · filed 2021-11-15 | 172.80K shares derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | 10.00K shares 10-Q · filed 2021-08-13 | 172.80K shares derived: sum of 3 quarters · filed 2022-03-30 | 172.80K shares derived: sum of 4 quarters · filed 2022-03-30 | ||||
| 2021-03-31 | 10.00K shares 10-Q · filed 2021-05-17 | 172.80K shares derived: sum of 2 quarters · filed 2022-03-30 | 172.80K shares derived: sum of 3 quarters · filed 2022-03-30 | |||||
| 2020-12-31 | 162.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 162.80K shares derived: sum of 2 quarters · filed 2022-03-30 | 327.64K shares 10-K · filed 2022-03-30 | |||||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 164.84K shares 10-Q · filed 2020-11-12 | ||||||
| 2020-06-30 | 164.84K shares 10-Q · filed 2020-08-11 | |||||||
| 2019-12-31 | 205.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | 205.25K shares derived: sum of 2 quarters · filed 2021-03-26 | 297.06K shares 10-K · filed 2021-03-26 | |||||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 91.81K shares 10-Q · filed 2019-11-14 | ||||||
| 2019-06-30 | 91.81K shares 10-Q · filed 2019-08-13 | |||||||
| 2018-12-31 | 127.59K shares 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |